Compare DexCom, Inc. (DXCM) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Invesco S&P 500 Low Volatility ETF — how do they compare? DexCom, Inc. trades at $77.86 (market cap $28.06B), while Invesco S&P 500 Low Volatility ETF trades at $76.57. The key difference: Invesco S&P 500 Low Volatility ETF is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals.
| DXCM | SPLV | |
|---|---|---|
Market Cap | $28.06B | — |
Sector | Health | — |
52-Week High | $89.53 | $77.45 |
52-Week Low | $54.84 | $70.30 |
Enterprise Value | $27.03B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
The Invesco S&P 500 Low Volatility ETF (SPLV) trades at $76.58, up 0.88% on the day, with a bullish technical signal from moving averages. The ETF provides exposure to 100 large-cap US stocks selected for their low historical volatility, offering a defensive tilt. Recent news highlights its role as a portfolio diversifier amid tech sell-offs and geopolitical tensions, with a scheduled dividend of $0.14 per share in June 2026.
SPLV offers a defensive equity strategy for investors seeking lower volatility than the broader market. The outlook is supported by its historical resilience during downturns, but its performance is inherently tied to market conditions that favor low-volatility factors. Key risks include underperformance during strong bull markets and the quarterly reconstitution of its underlying index.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
